Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, shared a post on LinkedIn:
“A privilege to be part of the 4th Antibody Drug Conjugates Workshop in Zurich, organized by ETOP IBCSG Partners Foundation.
This was not just another scientific meeting, but a highly selected and focused expert workshop, bringing together a limited group of international leaders from clinical oncology, translational research, drug development, and industry to discuss where the ADC field is truly heading.
From trial design to sequencing, from pulmonary toxicity to payload selection, from novel constructs to radio-immunoconjugates, the workshop captured both the complexity and the extraordinary potential of this rapidly evolving therapeutic class across tumour types, including breast, lung, GU, GI, and GYN cancers.
A sincere thank you to Rolf Stahel and Solange Peters for their vision, leadership, and scientific generosity in bringing this outstanding group together.
Proud to stand with colleagues and partners who are helping shape the next chapter of cancer care.”
Other articles featuring Antonio Passaro on OncoDaily.